Corcept Therapeutics Inc 1CORT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
A spot is opening up in the S&P 500, and these stocks are top candidates to fill the void
-
Corcept Resubmits FDA Application for Cushing Syndrome Drug
-
Corcept Plans to Resubmit Cushing's Syndrome Drug Application to FDA
-
Corcept Therapeutics Shares Climb on Positive Ovarian-Cancer Trial Results
-
Corcept Shares Fall as FDA Requires More Evidence for Hypercortisolism Drug Application
-
Corcept Says FDA Rejected Hypercortisolism Drug Application on Benefit-Risk Concerns
-
11 fast-growing small-cap stocks that could get a boost from the Fed's next move
-
11 fast-growing small-cap stocks that could -2-
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Shares Outstanding
- 108.10M
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- 293.30
- Price/Sales
- 17.50
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 730
- Website
- https://www.corcept.com
Valuation
|
Metric
|
1CORT
|
|---|---|
Price/Earnings (Normalized) | 293.30 |
Price/Book Value | 18.44 |
Price/Sales | 17.50 |
Price/Cash Flow | 108.72 |
Price/Earnings
1CORT
Financial Strength
|
Metric
|
1CORT
|
|---|---|
Quick Ratio | 2.50 |
Current Ratio | 2.86 |
Interest Coverage | — |
Quick Ratio
1CORT
Profitability
|
Metric
|
1CORT
|
|---|---|
Return on Assets (Normalized) | 15.74% |
Return on Equity (Normalized) | 20.11% |
Return on Invested Capital (Normalized) | 17.49% |
Return on Assets
1CORT
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|Wl#d<^ | LOCK|TNxyk | $129B | |||
| Moderna Inc
MRNA
| LOCK|#bW?^#F | LOCK|@mg | $85B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|xd^q@c | LOCK|>^mL | $79B | |||
| argenx SE ADR
ARGX
| LOCK|^zxxnKd | LOCK|WH^ | $52B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|>S&Z$Wr | LOCK|Z! | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|Q$t!%^> | LOCK|jX@b | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|KSQJcvZX | LOCK|^dQT | $26B | |||
| BioNTech SE ADR
BNTX
| LOCK|&KK$J> | LOCK|&Z | $24B | |||
| Incyte Corp
INCY
| LOCK|$jxp#^ | LOCK|<RK | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|!DSt!@ | LOCK|T? | $14B |
United States